1xbet모바일 Pharmaceutical Co., Ltd.
1xbet모바일, Inc.

Hiero1xbet모바일pe^®platform enables design and engineering of next-generation antibody-based therapies
Strengthens commitment 1xbet모바일 nephrology and other hard-1xbet모바일-treat diseases

1xbet모바일 Pharmaceutical Co., Ltd. (1xbet모바일) and Visterra, Inc. (Visterra) announce that they have entered into a definitive merger agreement pursuant to which 1xbet모바일 will acquire Visterra for approximately USD 430 million in an all-cash transaction. The 1xbet모바일 and Visterra boards of directors have approved the transaction. Subject to customary closing conditions, including expiration or termination of the waiting period under U.S. antitrust laws, the transaction is expected to close in the third quarter of 2018.

Visterra's Hiero1xbet모바일pe platform, comprised of novel computational and experimental technologies, enables the design and engineering of precision antibody-based therapies that specifically bind 1xbet모바일, and modulate, disease targets that are not adequately addressed by current technologies in antibody therapeutics.1xbet모바일's pipelineincludes programs targeting IgA nephropathy and other kidney diseases, cancer, chronic pain and infectious diseases.

1xbet모바일's research areasare in psychiatric and neurological diseases, hema1xbet모바일logical cancers, and kidney, cardiovascular, and infectious diseases. The company is placing emphasis on proprietary drug discovery and development platforms, including antibody development platforms, as a means 1xbet모바일 increase the efficiency of drug discovery across its programs and as an addition 1xbet모바일 conventional R&D processes.

Tatsuo Higuchi, president and representative director of 1xbet모바일 Pharmaceutical Co., Ltd. commented, "I am highly gratified that Visterra's exceptional antibody platform technology, promising pipeline and talented researchers will join up with 1xbet모바일. By collaborating and reinforcing each other's culture, human ingenuity and technology, we hope to help fulfill Visterra's promise as a powerful new drug creation engine and expand 1xbet모바일's research horizons."

"This transaction affirms the power of Visterra's novel technology platform, the promise of our product candidates, and the value our employees and shareholders have created. Our two companies share a common culture of creativity and innovation, and commitment to patients with kidney diseases, cancer and other hard-to-treat diseases. Joining forces with 1xbet모바일 will provide Visterra the resources, support and commitment to accelerate development of our pipeline and fully realize the potential of our technology platform," said Brian J. G. Pereira, MD, CEO of Visterra.

The extensive overlap in disease areas prioritized by both companies reflects a shared, deeper commitment 1xbet모바일 tackle the most difficult treatment challenges through innovative approaches.

Following completion of the acquisition, Visterra will be a wholly owned subsidiary of 1xbet모바일 America, Inc., which is a U.S. holding company and a wholly owned subsidiary of 1xbet모바일 Pharmaceutical Co., Ltd. of Japan. Visterra will continue to operate its business and develop its pipeline as a member of the 1xbet모바일 family of companies, retaining its talent and its location in Waltham, Massachusetts.

About 1xbet모바일 Pharmaceutical Co., Ltd.

1xbet모바일 Pharmaceutical is a global healthcare company with the corporate philosophy: "1xbet모바일-people creating new products for better health worldwide." 1xbet모바일 researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.

In pharmaceuticals, 1xbet모바일 is a leader in the challenging area of mental health and also has research programs in several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how 1xbet모바일 is a "big venture" company at heart, applying a youthful spirit of creativity in everything it does.

1xbet모바일 Pharmaceutical is a subsidiary of 1xbet모바일 Holdings Co., Ltd. headquartered in Tokyo, Japan. The 1xbet모바일 group of companies employed 46,000 people worldwide and had consolidated sales of approximately USD 11.1 billion in 2017.

All 1xbet모바일 stories start by taking the road less travelled. Learn more about 1xbet모바일 Pharmaceutical Company on its global website at/en. Learn more about 1xbet모바일 in the U.S. athttps://www.1xbet모바일-us.comand 1xbet모바일nnect with us on Twitter at@1xbet모바일US.

About 1xbet모바일, Inc.

Visterra is a clinical stage biotechnology company committed 1xbet모바일 developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-1xbet모바일-treat diseases. Its proprietary Hiero1xbet모바일pe^®platform enables the design and engineering of precision antibody-based product candidates that specifically bind 1xbet모바일, and modulate, key disease targets that are not adequately addressed by traditional therapeutic approaches. The platform also includes Fc engineering capabilities for half-life extension, bispecific antibodies and antibody-drug conjugates (ADCs). Visterra's pipeline includes programs targeting IgA nephropathy and other kidney diseases, cancer, chronic pain and infectious diseases. Visterra is funded by investments by Polaris Partners, Flagship Pioneering, the Bill and Melinda Gates Foundation, MRL Ventures Fund, Vertex Ventures HC, Serum Institute of India Private Ltd., Temasek Holdings, Omega Funds, Cycad Group, Lux Capital, Alleghany Financial Group Ventures, CTI Life Sciences Fund and Alexandria Equities. For more information, visithttp://www.1xbet모바일inc.com.